Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 1, 2004, Pages 199-205

  Buijk, Steven E ^a   Gyssens, I C ^a   Mouton, J W ^a,b   Metselaar, H J ^a   Groenland, T H ^a   Verbrugh, H A ^a   Bruining, H A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Antibiotics; Critical care; Desacetylcefotaxime; Pharmacodynamics; Surgery

Indexed keywords

AMPHOTERICIN B; CEFOTAXIME; COLISTIN; DEACETYLCEFOTAXIME; TOBRAMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CLEARANCE; LIVER TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MINIMUM INHIBITORY CONCENTRATION; PERIOPERATIVE PERIOD; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; REPERFUSION; SAMPLING;

ADULT; AGED; AREA UNDER CURVE; BILE; BIOTRANSFORMATION; BODY MASS INDEX; CEFOTAXIME; CEPHALOSPORINS; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SEX CHARACTERISTICS;

EID: 3543096869     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh268     Document Type: Article

References (27)

1. Kusne, S., Dummer, J. S., Singh, N. et al. (1988). Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) 67, 132-43.
2. Singh, N. (2000). The current management of infectious diseases in the liver transplant recipient. Clinics in Liver Disease 4, 657-73.
3. Miyata, T., Yokoyama, I., Todo, S. et al. (1989). Endotoxaemia, pulmonary complications, and thrombocytopenia in liver transplantation. Lancet ii, 189-91.
4. Wise, R., Wills, P. J., Andrews, J. M. et al. (1980). Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrobial Agents and Chemotherapy 17, 84-6.
5. Levy, M., Egersegi, P., Strong, A. et al. (1990). Pharmacokinetic analysis of cloxacillin loss in children undergoing major surgery with massive bleeding. Antimicrobial Agents and Chemotherapy 34, 1150-3.
6. Kuse, E., Vogt, P. & Rosenkranz, B. (1990). Pharmacokinetics of cefotaxime in patients after liver transplantation. Infection 18, 268-72.
7. Burckart, G. J., Ptachcinski, R. J., Jones, D. H. et al. (1987). Impaired clearance of ceftizoxime and cefotaxime after orthotopic liver transplantation. Antimicrobial Agents and Chemotherapy 31, 323-4.
8. MacGowan, A. P. & Bowker, K. E. (1998). Continuous infusion of beta-lactam antibiotics. Clinical Pharmacokinetics 35, 391-402.
9. Mouton, J. W. & Vinks, A. A. (1996). Is continuous infusion of beta-lactam antibiotics worthwhile? - efficacy and pharmacokinetic considerations. Journal of Antimicrobial Chemotherapy 38, 5-15.
10. Benko, A. S., Cappelletty, D. M., Kruse, J. A. et al. (1996). Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrobial Agents and Chemotherapy 40, 691-5.
11. Cockroft, D. W. & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41.
12. Pappas, G., Palmer, W. M., Martineau, G. L. et al. (1971). Hemodynamic alterations caused during orthotopic liver transplantation in humans. Surgery 70, 872-5.
13. Starzl, T. E., Iwatsuki, S. & Shaw, B. W. (1988). Techniques of liver transplantation. In Surgery of the Liver and Biliary Tract (Blumgart, I. H., Ed.), pp. 1537-1552. Churchill Livingstone, New York, USA.
14. Wise, R., Wright, N. & Wills, P. J. (1981). Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease. Antimicrobial Agents and Chemotherapy 19, 526-31.
15. Ings, R. M., Fillastre, J. P., Godin, M. et al. (1982). The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Reviews of Infectious Diseases 4, Suppl, S379-91.
16. Jehl, F., Peter, J. D., Picard, A. et al. (1987). Investigation of the biliary clearances of cefotaxime and desacetylcefotaxime by an original procedure in cholecystectomised patients. Infection 15, 450-4.
17. Westphal, J. F., Jehl, F., Schloegel, M. et al. (1993). Biliary excretion of cefixime: assessment in patients provided with T-tube drainage. Antimicrobial Agents and Chemotherapy 37, 1488-91.
18. Lecaillon, J. B., Rouan, M. C., Souppart, C. et al. (1982). Determination of cefsulodin, cefotiam, cephalexin, cefotaxime, desacetyl-cefotaxime, cefuroxime and cefroxadin in plasma and urine by high-performance liquid chromatography. Journal of Chromatography 228, 257-67.
19. Zwaveling, J. H., Maring, J. K., Klompmaker, I. J. et al. (2002). Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Critical Care Medicine 30, 1204-9.
20. Craig, W. A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26, 1-10; quiz 11-12.
21. Kemmerich, B., Lode, H., Belmega, G. et al. (1983). Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrobial Agents and Chemotherapy 23, 429-34.
22. Wise, R., Baker, S. & Livingston, R. (1980). Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrobial Agents and Chemotherapy 18, 369-71.
23. Arnow, P. M., Furmaga, K., Flaherty, J. P. et al. (1992). Microbiological efficacy and pharmacokinetics of prophylactic antibiotics in liver transplant patients. Antimicrobial Agents and Chemotherapy 36, 2125-30.
24. Doluisio, J. T. (1982). Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function. Reviews of Infectious Diseases 4, Suppl, S333-45.
25. Matzke, G. R., Abraham, P. A., Halstenson, C. E. et al. (1985). Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clinical Pharmacology and Therapeutics 38, 31-6.
26. Winston, D. J., Emmanouilides, C. & Busuttil, R. W. (1995). Infections in liver transplant recipients. Clinical Infectious Diseases 21, 1077-89.
27. Rowland, M. & Tozer, T. N. (1980). Clinical Pharmacokinetics: Concepts and Applications, 1 st edn. Lea & Febiger, PA, USA.